The estimated Net Worth of Steven D Ertel is at least $23.1 Million dollars as of 4 January 2017. Steven Ertel owns over 2,500 units of Acceleron Pharma Inc stock worth over $23,072,514 and over the last 11 years Steven sold XLRN stock worth over $68,600.
Sign up
Steven Ertel XLRN stock SEC Form 4 insiders trading
Steven has made over 30 trades of the Acceleron Pharma Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Steven sold 2,500 units of XLRN stock worth $68,600 on 4 January 2017.
The largest trade Steven's ever made was exercising 32,270 units of Acceleron Pharma Inc stock on 1 July 2016 worth over $156,187. On average, Steven trades about 7,762 units every 27 days since 2013. As of 4 January 2017 Steven still owns at least 129,077 units of Acceleron Pharma Inc stock.
You can see the complete history of Steven Ertel stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Acceleron Pharma Inc
Over the last 11 years, insiders at Acceleron Pharma Inc have traded over $211,038,855 worth of Acceleron Pharma Inc stock and bought 4,435,573 units worth $172,392,007 . The most active insiders traders include Corp /De/ Celgene, Richard F Pops, and Anthony B Evnin. On average, Acceleron Pharma Inc executives and independent directors trade stock every 10 days with the average trade being worth of $7,646,210. The most recent stock trade was executed by Adam M Veness on 9 November 2021, trading 4,500 units of XLRN stock currently worth $132,165.
What does Acceleron Pharma Inc do?
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
What does Acceleron Pharma Inc's logo look like?
Complete history of Steven Ertel stock trades at Acceleron Pharma Inc
Acceleron Pharma Inc executives and stock owners
Acceleron Pharma Inc executives and other stock owners filed with the SEC include:
-
Habib Dable,
President, Chief Executive Officer, Director -
Kevin McLaughlin,
Chief Financial Officer, Senior Vice President, Treasurer -
Sujay Kango,
Executive Vice President and Chief Commercial Officer -
Ravindra Kumar,
Senior Vice President, Chief Scientific Officer -
Francois Nader,
Independent Chairman of the Board -
Joseph Zakrzewski,
Independent Director -
Terrence Kearney,
Independent Director -
Thomas McCourt,
Independent Director -
Karen Smith,
Independent Director -
Todd James,
Senior Vice President Corporate Affairs and Investor Relations -
Kemal Malik,
Independent Director -
Christopher Hite,
Director -
Laura Hamill,
Director -
Jay Backstrom,
Executive Vice President - Research and Development -
Terrance Mcguire,
Director -
Tom Maniatis,
Director -
Jean George,
Director -
John L Knopf,
CEO and President -
Steven D Ertel,
SVP & Chief Business Officer -
Matthew L Sherman,
SVP & Chief Medical Officer -
Richard F Pops,
Director -
Adam M Veness,
SVP, General Counsel and Sec. -
John D Quisel,
EVP, Chief Business Officer -
Christopher Rovaldi,
SVP, Program Mgmt and Ops -
Robert K Zeldin,
EVP & Chief Medical Officer -
Corp /De/ Celgene,
10% owner -
Anthony B Evnin,
Director -
Edwin M Jr Kania,
Director -
Venture Management Co Iv Ll...,
-
Venture Management Co Iv Ll...,
-
Advisors Llcorbimed Capital...,
-
Corp /De/Bristol Myers Squi...,